Aureka Biotechnologies announced the close of a US$100 million Series B financing. Granite Asia funded the first tranche exclusively, and a prominent strategic investor led a subsequent tranche, with participation from HighLight Capital (HLC) and follow-on investment from existing shareholders including MPCi and NRL Capital. Aureka has now raised nearly US$200 million to date.
The company will direct proceeds primarily toward research and large-scale training of its next generation of biological foundation models, further strengthening performance on core tasks such as de novo molecular design, biological structure modeling and function prediction. Aureka will also upgrade Lab-in-the-Loop, its experiment-centered feedback engine, strengthening the closed-loop between those models and its proprietary single-cell functional screening, high-throughput experimental validation and drug development platforms.
With its closed-loop, AI-native infrastructure already built, Aureka is now strengthening the intelligence core of that system: its foundation models. Aureka combines large-scale pre-training, project-specific post-training, AI agents and experiments that run at scale into AI-for-Science infrastructure for the life sciences. In it, models do not just solve individual drug discovery tasks; they learn the rules of biology, to understand, generate, predict and intervene in complex biological systems.
As foundation models and automated R&D converge, Aureka is shifting from using AI to make drug discovery more efficient to using AI to model living systems, pushing both the technical frontier and the commercial ceiling of AI-driven drug discovery.